RedHill Biopharma Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (14)

Latest Posts

About This Stock More About This Stock
RedHill's R&D Day Highlights Potential For Bekinda
Article By: Jason Napodano
Thursday, April 27, 2017 1:57 PM EDT
RedHill Biopharma Ltd held an R&D Day highlighting for investors the clinical and commercial attributes of BEKINDA (RHB-102).
In this article: RDHL
Read
Yeliva Granted Orphan Drug Designation In Cholangiocarcinoma
Article By: Jason Napodano
Tuesday, April 4, 2017 3:58 PM EDT
I ultimately believe that RedHill will look to partner Yeliva for Phase 3 development, and RedHill is certainly well-funded today with $66 million on hand as of December 2016, but every bit of financial assistance helps.
In this article: RDHL
Read
RedHill Expects Bekinda Top-Line Data In Q2
Article By: Jason Napodano
Monday, February 13, 2017 2:05 PM EDT
RedHill Biopharma Ltd. announced that the final patient has been enrolled in the company's Phase 3 clinical study examining Bekinda as a treatment for acute gastroenteritis and gastritis.
In this article: RDHL
Read
MS An Interesting Upshot Opportunity For RedHill's RHB-104
Article By: Jason Napodano
Tuesday, December 13, 2016 12:14 PM EDT
RedHill has numerous catalysts on the horizon that should make the next six to nine months a good time to be a shareholder, including the potential closing of a product acquisition or in-licensing in the next few weeks.
In this article: RDHL
Read
RedHill Expects An Eventful Next Few Months
Article By: Jason Napodano
Wednesday, November 16, 2016 2:41 PM EDT
RedHill's stock has taken a bit of a hit over the past few months. The shares peaked at over $16 in August 2016 and have pulled back to $11 today.
In this article: RDHL
Read

PARTNER HEADLINES

Latest Tweets for $RDHL

No tweets yet!